In addition, a combination of acetylcholinesterase inhibitor (AChEI) and inactivating the STAT3 pathway with MMPP treatment is a therapy of greater benefit in AD patients than taking AChEIs alone (Parsons et al. 2013; Park et al. 2013). The gene discussed is ACHE; the disease is Alzheimer disease.